In the general population, host glycomic alterations, in particular, loss of galactose (agalactosylation; measured as high levels of G-ratio and G0 glycan groups), on circulating IgG, drive inflammation and precede the onset of premature aging-associated diseases. We investigated whether glycomic alterations, in particular agalactosylation, precede the development of non-AIDS-defining cancers during antiretroviral therapy (ART)-suppressed HIV infection.
In a longitudinal case-control study, 104 plasma samples were collected between 13.8 and -0.8 years before the onset of cancer in 29 HIV+ ART+ cases; 10 with gastrointestinal (GI) cancers, 9 with skin cancers, and 10 with other non-AIDS-defining cancers. Control samples (121) were collected, at same time-points as cases, from 32 matched (for age at sample collection, sex, and ethnicity) HIV+ ART+ controls without cancers. IgG glycosylation was profiled using capillary electrophoresis, and soluble markers of inflammation were measured by multiplex cytokine arrays. Mann–Whitney and Spearman’s rank tests were used for statistical analyses. False discovery rates (FDR) were calculated to account for multiple comparisons.
Several markers of inflammation (including IFN-?, IFN-?, IP-10, IL-10, and galectin-1) were higher in cases (before cancer onset) compared to controls (FDR<0.05; Fig 1A). No differences were observed in G-ratio or G0 glycans between cases and controls when considering all cancers; however, levels of G-ratio and G0 were significantly higher in cases with GI cancers compared to controls (FDR<0.01; Fig 1B). Differences in soluble inflammatory markers between cases and controls were observed 2-5 years before cancer onset (example in Fig 1C; P<0.01). Differences in G-ratio and G0 between GI cancer cases and controls were observed 5-10 years before cancer onset (Fig 1D; P<0.05). Finally, pro-inflammatory IgG glycans correlated with higher inflammation (Fig 1E; P<0.05), whereas anti-inflammatory IgG glycans correlated with lower inflammation (Fig 1E; P<0.05).
Our exploratory study suggests that premature-aging-associated glycomic dysregulations and pro-inflammatory responses may precede the onset of non-AIDS-defining cancers, especially inflammation-associated cancers such as GI cancers, during ART+ HIV infection. Potential glycomic and inflammatory pathways fostering cancer progression, during ART-suppressed HIV infection, warrant further investigation into their prognostic and functional significance.